Wojciech Makarewicz

Wojciech Makarewicz

Auto-generated profile, based on publicly available information

Wojciech Makarewicz

Department of Surgical Oncology, Medical University of Gdańsk, Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2007 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RWRudolf A. Weiner
Rudolf A. Weiner
SWSylvia Weiner
Sylvia Weiner
IPIngmar Pomhoff
Ingmar Pomhoff
CJChristoph Jacobi
Christoph Jacobi
WMWojciech Makarewicz
Wojciech Makarewicz
GWGerhard Weigand
Gerhard Weigand

26 May 2020 in Gut Microbes
Verified
Journal Article
Open access
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
ADAgnieszka Daca
Agnieszka Daca
MFMateusz Fic
Mateusz Fic
TWThierry van de Wetering
Thierry van de Wetering
MFMarcin Folwarski
Marcin Folwarski
WMWojciech Makarewicz
Wojciech Makarewicz
The link between gut microbiota and the development of colorectal cancer has been investigated. An imbalance in the gut microbiota promotes the progress of colorectal carcinogenesis via multiple mechanisms, including inflammation, activation of carcinogens, and tumorigenic pathways as well as damaging host DNA. Several therapeutic methods are available with which to alter the composition and the activity of gut microbiota, such as administration of prebiotics, probiotics, and synbiotics; these can confer various benefits for colorectal cancer patients. Nowadays, fecal microbiota transplantation is the most modern way of modulating the gut microbiota. Even though data regarding fecal microbiota transplantation in colorectal cancer patients are still rather limited, it has been approved as a clinical method of treatment-recurrent Clostridium difficile infection, which may also occur in these patients. The major benefits of fecal microbiota transplantation include modulation of immunotherapy efficacy, amelioration of bile acid metabolism, and restoration of intestinal microbial diversity. Nonetheless, more studies are needed to assess the long-term effects of fecal microbiota transplantation. In this review, the impact of gut microbiota on the efficiency of anti-cancer therapy and colorectal cancer patients’ overall survival is also discussed.

29 May 2020 in Current Microbiology
Verified
Journal Article
Open access
PDF file
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
JRJakub Ruszkowski
Jakub Ruszkowski
MFMateusz Fic
Mateusz Fic
MFMarcin Folwarski
Marcin Folwarski
WMWojciech Makarewicz
Wojciech Makarewicz
The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens’ virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of S. boulardii administration was tested in variety of human diseases. We discussed the results of S. boulardii CNCM I-745 use in the treatment or prevention of Helicobacter pylori infections, diarrhoea (Clostridium difficile infections, antibiotic-associated diarrhoea, and traveller’s diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of S. boulardii. Administration of S. boulardii CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because—due to its fungal natural properties—it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following S. boulardii CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain.

22 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
ADAleš Dvořák
Aleš Dvořák
MFMarcin Folwarski
Marcin Folwarski
ADAgnieszka Daca
Agnieszka Daca
KPKatarzyna Przewłócka
Katarzyna Przewłócka
WMWojciech Makarewicz
Wojciech Makarewicz
The association between bacterial as well as viral gut microbiota imbalance and carcinogenesis has been intensively analysed in many studies; nevertheless, the role of fungal gut microbiota (mycobiota) in colorectal, oral, and pancreatic cancer development is relatively new and undiscovered field due to low abundance of intestinal fungi as well as lack of well-characterized reference genomes. Several specific fungi amounts are increased in colorectal cancer patients; moreover, it was observed that the disease stage is strongly related to the fungal microbiota profile; thus, it may be used as a potential diagnostic biomarker for adenomas. Candida albicans, which is the major microbe contributing to oral cancer development, may promote carcinogenesis via several mechanisms, mainly triggering inflammation. Early detection of pancreatic cancer provides the opportunity to improve survival rate, therefore, there is a need to conduct further studies regarding the role of fungal microbiota as a potential prognostic tool to diagnose this cancer at early stage. Additionally, growing attention towards the characterization of mycobiota may contribute to improve the efficiency of therapeutic methods used to alter the composition and activity of gut microbiota. The administration of Saccharomyces boulardii in oncology, mainly in immunocompromised and/or critically ill patients, is still controversial.

12 April 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Adriana MikaAdriana Mika
Adriana Mika
APAlicja Pakiet
Alicja Pakiet
ACAleksandra Czumaj
Aleksandra Czumaj
ZKZbigniew Kaczyński
Zbigniew Kaczyński
ILIvan Liakh
Ivan Liakh
TŚTomasz Śledziński
Tomasz Śledziński
Recent evidence suggests that lipid composition in cancer tissues may undergo multiple alterations. However, no comprehensive analysis of various lipid groups in colorectal cancer (CRC) tissue has been conducted thus far. To address the problem in question, we determined the contents of triacylglycerols (TG), an energetic substrate, various lipids necessary for cell membrane formation, among them phospholipids (phosphatidylcholine, phosphatidylethanolamine), sphingolipids (sphingomyelin) and cholesterol (free, esterified and total), and fatty acids included in complex lipids. 1H-nuclear magnetic resonance (1H-NMR) and gas chromatography-mass spectrometry (GC-MS) were used to analyze the lipid composition of colon cancer tissue and normal large intestinal mucosa from 25 patients. Compared with normal tissue, cancer tissues had significantly lower TG content, along with elevated levels of phospholipids, sphingomyelin, and cholesterol. Moreover, the content of oleic acid, the main component of TG, was decreased in cancer tissues, whereas the levels of saturated fatty acids and polyunsaturated fatty acids (PUFAs), which are principal components of polar lipids, were elevated. These lipidome rearrangements were associated with the overexpression of genes associated with fatty acid oxidation, and the synthesis of phospholipids and cholesterol. These findings suggest that reprogramming of lipid metabolism might occur in CRC tissue, with a shift towards increased utilization of TG for energy production and enhanced synthesis of membrane lipids, necessary for the rapid proliferation of cancer cells.

6 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Adriana MikaAdriana Mika
Adriana Mika
JKJaroslaw Kobiela
Jaroslaw Kobiela
APAlicja Pakiet
Alicja Pakiet
ACAleksandra Czumaj
Aleksandra Czumaj
ESEwa Sokołowska
Ewa Sokołowska
TŚTomasz Śledziński
Tomasz Śledziński
Although a growing body of evidence suggests that colorectal cancer (CRC) is associated with alterations of fatty acid (FA) profiles in serum and tumor tissues, available data about polyunsaturated fatty acid (PUFA) content in CRC patients are inconclusive. Our study showed that CRC tissues contained more PUFAs than normal large intestinal mucosa. However, serum levels of PUFAs in CRC patients were lower than in healthy controls. To explain the mechanism of PUFA alterations in CRC, we measured FA uptake by the colon cancer cells and normal colon cells. The levels of PUFAs in colon cancer cell culture medium decreased significantly with incubation time, while no changes were observed in the medium in which normal colon cells were incubated. Our findings suggest that the alterations in tumor and serum PUFA profiles result from preferential uptake of these FAs by cancer cells; indeed, PUFAs are essential for formation of cell membrane phospholipids during rapid proliferation of cancer cells. This observation puts into question potential benefits of PUFA supplementation in CRC patients.